Hypothesis

We propose that age‑dependent increases in nuclear lamina stiffness alter the accessibility of chromatin to the nuclease DNASE1L3, biasing cfDNA release toward longer fragments that retain methylation marks characteristic of heterochromatin‑rich repeats. This mechanistic link explains the concurrent shift in cfDNA size distribution and methylation patterns observed in aging plasma and predicts that interventions that modulate lamina rigidity will concomitantly reshape both fragment length and epigenetic signatures.

Mechanistic Basis

1. Lamina stiffness and chromatin compaction – Lamin A/C accumulation and post‑translational modifications increase nuclear rigidity in senescent cells, limiting the formation of chromatin loops that expose nucleosome‑protected DNA to intracellular nucleases.
2. DNASE1L3 cleavage preference – DNASE1L3 generates cfDNA with A/C/T end motifs after stepwise cleavage; a stiffer lamina reduces the probability of generating short, nucleosome‑sized fragments because the enzyme encounters fewer accessible linker regions, favoring release of longer, protected fragments that span multiple nucleosomes.
3. Cell‑type specificity – Neutrophils and colon epithelial cells exhibit pronounced lamina remodeling with age, consistent with the observed increase in their cfDNA contributions ([1][5]). In contrast, NK cells, which retain a more pliable lamina, show decreased cfDNA release.
4. Methylation retention – Longer fragments preserve methylation patterns of repeat elements (e.g., LINE‑1) that are otherwise lost in short cfDNA due to preferential degradation of unmethylated, open chromatin. Thus the observed enrichment of age‑related methylation in exons, promoters, and repeats reflects the selective survival of heterochromatin‑derived DNA.

Testable Predictions

• Prediction 1: In vitro senescence induced by lamin A/C overexpression will produce cfDNA with a higher proportion of fragments >175 bp and increased methylation at LINE‑1 CpGs compared with control senescent cells lacking lamin overexpression.
• Prediction 2: Pharmacological softening of the nuclear lamina (e.g., using Lamin A/C‑targeting siRNA or small‑molecule inhibitors of farnesylation) in aged mice will shift plasma cfDNA toward shorter fragments and reduce the age‑associated methylation signal at the 48‑CpG clock sites.
• Prediction 3: Neutrophil‑derived cfDNA isolated from aged individuals will show a stronger correlation between lamina stiffness markers (e.g., phosphorylated lamin A/C) and fragment length than cfDNA from lymphocytes.

Experimental Design

• Cell culture: Compare cfDNA released from primary human neutrophils cultured under normoxic conditions, with and without lamin A/C overexpression (lentiviral vector) or CRISPR‑mediated LMNA knock‑down. Measure fragment size via Bioanalyzer, end motifs via nanopore sequencing, and methylation via targeted bisulfite sequencing of the 48‑CpG panel and LINE‑1.
• Animal model: Treat aged (20‑month) C57BL/6 mice with a farnesyltransferase inhibitor (FTI) for 4 weeks. Collect plasma at baseline and weekly; assess cfDNA size distribution, methylation age using the 48‑CpG model, and lamina phosphorylation in isolated neutrophils via flow cytometry–based immunofluorescence.
• Human validation: Correlate plasma lamin A/C phosphorylation levels (measured by ELISA) with cfDNA fragment length percentages and methylation age in a cohort of 100 participants spanning 20‑80 years.

Potential Confounds and Controls

• Apoptosis vs necrosis: Include caspase‑3 activity assays to ensure observed cfDNA changes are not driven by altered cell death modes.
• Inflammation: Measure circulating IL‑6 and TNF‑α to control for systemic inflammatory influences on cfDNA release.
• Technical bias: Spike in synthetic cfDNA fragments of known size and methylation to normalize library preparation artifacts.

If the predictions hold, this hypothesis would establish a causal chain linking nuclear mechanics to the dual epigenetic and fragment‑size signatures of aging cfDNA, offering a mechanistic target for interventions aimed at modulating biological age readouts.

References [1] https://pmc.ncbi.nlm.nih.gov/articles/PMC11318736/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC12905613/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC5945531/ [4] https://www.pnas.org/doi/10.1073/pnas.2220982120 [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC10334733/ [6] https://pubmed.ncbi.nlm.nih.gov/41591979/ [7] https://aacrjournals.org/cancerres/article/85/9/1696/762054/Integrating-Plasma-Cell-Free-DNA-Fragment-End